Stocktoria
Nexentis Technologies Inc. NXTS
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2010-05-26
Nexentis Technologies Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | $210,000 | $263,445 | $394,004 | $438,141 |
| Gross profit | — | $45,000 | $208,000 | $235,691 | $302,198 |
| R&D expense | $179,000 | $369,000 | $1.9M | $770,826 | $538,684 |
| Operating income | -$4.2M | -$3.3M | -$7.6M | -$5.8M | -$4.7M |
| Interest expense | — | $16 | — | — | — |
| Income tax | -$18,000 | — | — | — | — |
| Net income | -$4.0M | -$5.2M | -$6.5M | -$5.7M | -$4.8M |
| EPS (diluted) | $-8.61 | $-27.74 | $-5.43 | $10.85 | — |
| Operating cash flow | -$3.8M | -$3.4M | -$3.2M | -$5.1M | -$4.1M |
| Free cash flow | -$3.8M | — | — | -$5.1M | -$4.2M |
| Cash & equivalents | $3.8M | $1.9M | $4.4M | $5.7M | $6.8M |
| Inventory | — | $21,000 | $122,000 | $81,706 | $22,603 |
| Total assets | $20.4M | $5.5M | $7.2M | $6.5M | $7.6M |
| Total liabilities | $4.7M | $892,000 | $786,000 | $754,872 | $1.2M |
| Shareholders' equity | $16.0M | $4.7M | $6.5M | $5.8M | $6.5M |
Source: SEC EDGAR filings · CIK 0001789192 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.